Advanced Pipeline
| Product / Indication | Pre Clinical | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|---|
Autologous BCDA-01 : CardiAMP Cell TherapyIndication : Ischemic Heart Failure (NCT# 02438306) |
|
||||
Autologous BCDA-02 : CardiAMP Cell TherapyIndication : Chronic Myocardial Ischemia (NCT# 03455725) |
|
||||
NK1R+ Allogenic BCDA-03: CardiALLO Cell TherapyIndication : Ischemic Heart Failure |
|
||||
NK1R+ Allogenic BCDA-04: CardiALLO Cell TherapyIndication: COVID-19 ARDS |
|
||||
Helix Partner: CellProtheraIndication: Acute Infarction (EXCELLENT NCT# 02669810) |
Funded by Partner |
||||
Helix Partner: Centro Cardiologico MonzinoIndication: Heart Failure (RECARDIO NCT# 02059681) |
Funded by Partner |
||||
- CardiAMP – autologous minimally processed bone marrow cells (a patient’s own cells)
- NK1R+ MSC –allogenic culture expanded mesenchymal stem cells derived from bone marrow (donor-derived)
Both programs provide compelling and synergistic approaches to replicating the natural response of bone marrow cells to cardiac injury. CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, using a pre-procedure screening test to identify patients most likely to benefit from the therapy. NK1R+ MSCs utilize younger, universal donor mesenchymal stem cells and may be appropriate for patients who are not optimal candidates for the CardiAMP therapy.
The NK1R+ MSC platform is also being advanced clinically for the pulmonary indication of acute respiratory distress.News
Empowered Patient Podcast
UW Health
Greenbay CBS
Henry Ford Health System
press releases
11 May CALL US NOW
EMAIL US NOW